Poly Medicure Limited has informed the Exchange about Statement on Declaration of Unmodified opinion for the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.6 pts less than Nifty Smallcap 250 and 4.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure Limited reported audited financial results for Q4 and FY ended March 31, 2026 with an unmodified (clean) audit opinion from both standalone and consolidated perspectives. Standalone profit after tax surged significantly to Rs. 3,359.85 lakhs from Rs. 865.60 lakhs in the previous year, while consolidated PAT grew modestly to Rs. 3,338.58 lakhs from Rs. 3,207.30 lakhs. The board recommended a dividend of Rs. 3.5 per equity share (70% on Rs. 5 face value), subject to shareholder approval. During the year, the company completed two major acquisitions: Pendracare Group (with provisional accounting under Ind AS 103) and Citeffe Group (finalized acquisition accounting), contributing to consolidated goodwill. An exceptional item of Rs. 45.07 lakhs was recognized for impact of new Labour Codes. The statutory auditors (Doogar & Associates) expressed unmodified opinions on both standalone and consolidated results.
Strong standalone profitability with clean audit opinions is positive for investor confidence. The recommended dividend at 70% payout signals management's optimism. Acquisitions may provide future growth but include provisional accounting and contingent consideration.